Monkeypox Outbreak Occurs After Moderna Begins Testing Monkeypox mRNA Shot in U.K. Clinical Trial
Can mpox mRNA-1769 jab shed onto unvaccinated?
The seventh case of “ultra-deadly” monkeypox (mpox) strain has now been detected in the U.K., following clinical trials for Moderna’s mRNA mpox injection that began in the country in March 2024.
Follow Jon Fleetwood: Instagram @realjonfleetwood / Twitter @JonMFleetwood / Facebook @realjonfleetwood
The timing raises questions about whether the trial and the appearance of the disease are connected, as hundreds of participants received the monkeypox jab.
“The mPower Trial is a clinical trial conducted by Moderna to evaluate the safety of, and immune response to, an investigational vaccine called mRNA-1769, which aims to protect against illness caused by the mpox (previously called monkeypox) virus,” an announcement reads, describing the program that began in March of last year.
“‘Investigational’ means it has not been approved by the MHRA or another health regulatory authority.”
The study was carried out by the National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN).
NIHR Director of Strategic Partnerships Dr. Matthew Hallsworth said at the time: “We’re really pleased that Moderna has chosen to run its mpox trial in the UK. This demonstrates our strength in clinical research,” according to an NIHR press release.
Dr. Hallsworth raised the possibility of “future pandemics” striking the U.K.
“Our partnership with Moderna ensures UK research is at the cutting edge of new vaccine technologies with the potential to protect against global health threats such as mpox and future pandemics,” he added.
“We hope that recruitment to this trial will be as successful as the Covid-19 vaccine trials that were run in the UK and we encourage the public to help out where they can - whether that’s by volunteering or encouraging others.”
Just seven months after the mRNA mpox shot trial began, the U.K. Health Security Agency (UKHSA) announced the first human case of the more severe ‘clade Ib’ mpox virus to be reported in the country had been detected in London.
Mainstream reports failed to mention Moderna’s vaccination trial, instead connecting the infection with the patient’s recent travels.
Per The Pharmaceutical Journal:
On 30 October 2024, Susan Hopkins, chief medical adviser at the UKHSA, said that the infected patient had travelled to unnamed African countries on holiday and returned to London on an overnight flight on 21 October 2024.
“They developed initial flu-like symptoms more than 24 hours later, and then, subsequently, on the 24 October, started to develop a rash, which progressed over subsequent days, and attended an emergency department in London where they were swabbed, tested and sent home to isolate whilst the results were pending,” she said.
Nevertheless, the timing is uncanny.
And today, the U.K.’s Daily Mail is reporting the seventh case of the mpox clade 1b strain has been detected in the country.
That report pointed to the patient’s travels, too, and again failed to mention the Moderna trial:
Another case of the new deadly mpox strain has been detected in the UK, health officials confirmed today.
The clade 1b mutation, which experts have called ‘the most dangerous one so far’ kills one in ten of those infected and is believed to be behind a wave of miscarriages.
It takes the total number of confirmed cases in Britain now to seven.
Officials don’t yet know how they became infected with the strain.
But they had ‘recently’ travelled back to the UK from Uganda, the UK Health Security Agency (UKHSA) said.
Mpox symptoms include fever, swollen lymph nodes, and a painful rash with blister-like lesions that progress to scabs.
Recent studies in Cell and Nature show the Moderna mRNA mpox shot doesn’t fully prevent infection or transmission, as vaccinated animals still showed viral replication.
Its effectiveness is short-lived, depends on high doses, and has major gaps in long-term protection and real-world performance.
It’s worth noting that blistering is a symptom linked to Pfizer’s COVID-19 mRNA jab, according to the pharmaceutical giant’s data.
The emergence of a deadlier mpox strain, just months after the launch of Moderna’s mRNA mpox trial, coupled with studies showing limited efficacy and concerning side effects, raises serious questions about the connections between experimental mRNA technology and the rise of new, more dangerous public health threats.
People injected with Moderna’s mRNA mpox jab could develop mpox-like symptoms due to inflammatory or autoimmune reactions triggered by the body producing the viral protein encoded by the mRNA, such as blistering or rashes resembling mpox lesions.
Additionally, if lipid nanoparticles containing the mRNA or mpox proteins are excreted through bodily fluids like sweat, saliva, or breath, there is a theoretical risk of shedding onto the unvaccinated, which has been observed as a concern with other mRNA vaccines.
A February 2024 preprint study showed that mRNA COVID-19 shot components, such as lipid nanoparticles and spike proteins, may not be confined to the vaccinated individual but could potentially be shed to others through blood transfusion, organ transplantation, breastfeeding, exhalation, skin contact, or sexual intercourse.
The potential for shedding raises questions about exposure to- and immune reactions in those who did not receive the Moderna mpox injection.
Other monkeypox vaccine formulations, like Emergent BioSolutions’ ACAM2000, which contains a live virus, have demonstrated that the vaccinated can spread to and even kill those who have not received the jab.
BioNTech, who partnered with Pfizer for its mRNA COVID jab, is also developing an mRNA vaccine for mpox in a Phase I/II study (NCT05988203), due to roll out in mid-2025.
Follow Jon Fleetwood: Instagram @realjonfleetwood / Twitter @JonMFleetwood / Facebook @realjonfleetwood
Death Reported in Unvaccinated Individuals Infected by Those Vaccinated for Monkeypox: FDA Package Insert
The monkeypox vaccine ACAM2000 contains a live virus that the vaccinated can spread to and even kill those who have not received the jab, according to the U.S. Food and Drug Administration (FDA).
Ebola Vaccine That 'Sheds' in 31% of Vaccinated Given to Colorado Healthcare Workers Just Down the Road from New Bat Lab
Editor’s note: This article’s headline has been updated to clarify that the FDA insert for Merck’s ERVEBO Ebola vaccine states that the vaccine “sheds” in more than 31% of those vaccinated with the drug. The prior headline said that the vaccine “‘Sheds’ Onto/Infects Others 31% of the Time.” It is more precise to simply say that the vaccine “sheds” in 31…
COVID Vaccinated Could Shed Lipid Nanoparticles, Spike Protein Through Blood Transfusion, Breastmilk, Organ Transplantation, Exhalation, Skin-to-Skin Contact: New Preprint Study
A new study made available online today in preprint analyzes exposure to COVID-19 vaccine components such as lipid nanoparticles or spike protein.
FDA Approves AstraZeneca No-Needle At-Home 'Live' Virus Flu Vaccine with 90% Shed Rate
In September, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s FluMist for self or caregiver administration for the 2024-2025 influenza season.
MRNA-1769 codes for Glycoprotein B8R, the protein used by the Mpox virus to attach to epithelial cells that line EXTERIOR mucosal body surfaces. The problem is, when you inject the message to make the protein INSIDE the body, some of the normal tissue cells making this protein will get destroyed by the immune system before the protein gets released. This will result in varying degrees of loss of tissue and pathology every time. However, not all the cells making the protein will get destroyed, so proteins will get released into the blood and lymph. The idea is to have the body make antibodies against those proteins, but it takes a couple of weeks for that to happen. So, in the meantime, those proteins will attach to the linings of blood vessels, connective tissue and keratinocytes in the skin, and neurons. This will cause inflammation that will weaken epithelial barriers making an Mpox infection more likely to occur. It will also cause adverse effects affecting the circulatory system and the nervous system not generally associated with an Mpox infection. And yes, the lipid nanoparticle delivery system is prone to shedding events.
THERE ARE NO ACCIDENTS!. They use that as excuses. Everything is planned.
Every "infection", outbreak, happens in a chemical laboratory, first. Evil evil evil.
We must understand, these globalists, demons, satan followers, lie lie lie.
When researchers/scientists/medical studies prove otherwise, they continue
to say their original lies. They do not know how to tell the truth. They care not about
human life at all. Its' about steal, kill, and destroy..dominate and control. Peace to all.